CN102793973B - Parkinson's disease treatment device - Google Patents

Parkinson's disease treatment device Download PDF

Info

Publication number
CN102793973B
CN102793973B CN 201210275424 CN201210275424A CN102793973B CN 102793973 B CN102793973 B CN 102793973B CN 201210275424 CN201210275424 CN 201210275424 CN 201210275424 A CN201210275424 A CN 201210275424A CN 102793973 B CN102793973 B CN 102793973B
Authority
CN
China
Prior art keywords
parkinson
stimulation
system
disease treatment
neurotransmitter
Prior art date
Application number
CN 201210275424
Other languages
Chinese (zh)
Other versions
CN102793973A (en
Inventor
鲁艺
王立平
张元元
钟成
蔚鹏飞
刘楠
Original Assignee
中国科学院深圳先进技术研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国科学院深圳先进技术研究院 filed Critical 中国科学院深圳先进技术研究院
Priority to CN 201210275424 priority Critical patent/CN102793973B/en
Publication of CN102793973A publication Critical patent/CN102793973A/en
Application granted granted Critical
Publication of CN102793973B publication Critical patent/CN102793973B/en

Links

Abstract

本发明涉及一种帕金森氏病治疗装置,该装置包括电生理信号发生检测系统、给药系统、光刺激系统及中央处理系统,中央处理系统控制电生理信号发生检测系统、给药系统及光刺激系统。 The present invention relates to a Parkinson's disease treatment apparatus, the apparatus comprises a detection signal generating electrophysiological systems, delivery systems, and optical stimulation system central processing system, the central processing system controls electrophysiological signal generating detection system, and a light delivery system stimulation system. 电生理信号发生检测系统包括神经递质传感器、记录电极和刺激电极;给药系统包括注射泵及微导管,中央处理系统控制注射泵通过微导管进行药物缓释;光刺激系统包括波形发生器、光源及光纤,波形发生器控制光源发出的激光的频率,光源发出的激光传至所述光纤中用于对导入有光敏感基因的神经组织细胞进行光刺激治疗。 Electrophysiological signal generating sensor detection system comprises a neurotransmitter, a recording electrode and a stimulating electrode; drug delivery system comprises a microcatheter and a syringe pump, the syringe pump control central processing system through a microcatheter drug release; light stimulation system comprises a waveform generator, and an optical fiber light source, the waveform generator controls the frequency of the laser light source emits laser light emitted transmitted to the optical fiber for introducing an optical neural cells sensitive to light stimulation of gene therapy. 为帕金森氏病的治疗提供一种监测和治疗效果较好且较为安全的装置。 It provides a better monitoring and treatment apparatus and safer for the treatment of Parkinson's disease.

Description

帕金森氏病治疗装置 Parkinson's disease treatment device

技术领域 FIELD

[0001] 本发明涉及医疗器械领域,特别是涉及一种帕金森氏病治疗装置。 [0001] The present invention relates to the field of medical devices, particularly to a Parkinson's disease treatment device.

背景技术 Background technique

[0002] 帕金森氏病(Parkinson's disease)是一种中老年人常见的中枢神经系统变性疾病,多在60岁以后发病,主要病症表现为患者动作缓慢,手脚或身体其它部分的震颤,身体失去柔软性,变得僵硬,晚期会导致患者生活不能自理,给病人及家属带来较大负担。 [0002] Parkinson's disease (Parkinson's disease) is common in the elderly degenerative disease of the central nervous system, the multi-onset after age 60, the main symptoms of the disease is slow patient, hands or tremors other parts of the body, the body loses softness, become stiff, can cause patients with advanced life can not take care of themselves, to bring greater burden on patients and their families. 此外, 随着全球人口逐渐向老龄化过渡,帕金森氏病等神经系统疾病明显增多并逐渐成为一大社会负担。 In addition, with the gradual transition to the global population aging, neurological diseases such as Parkinson's disease increased significantly and has become a major burden on society.

[0003] 近些年,神经调节治疗在治疗帕金森氏病等神经系统疾病的应用中得到快速发展,目前已发展了多种神经调节治疗方法,比如重复经颅磁刺激、经颅直接电刺激和深脑电刺激等,其中,深脑电刺激疗法是目前较为理想的神经调节治疗方法之一。 [0003] In recent years, therapies for neuromodulation in the treatment of neurological diseases such as Parkinson's disease rapid development, has developed a variety of methods neuromodulation therapy, such as repetitive transcranial magnetic stimulation, direct electrical transcranial stimulation deep Brain stimulation and the like, which is one of deep brain electrical stimulation neuromodulation therapy currently more desirable.

[0004] 深脑电刺激具有一定的治疗效果,但是也存在许多不足:首先,深脑电刺激缺乏选择性和特异性,并且在许多情况下对于治疗的机理并不明确,因此,在刺激的过程中有一定的不可预知性,甚至可能会产生副作用。 [0004] deep brain electrical stimulation has a therapeutic effect, but there are also many deficiencies: First, deep brain electrical stimulation of the lack of selectivity and specificity, and in many cases for the mechanism of treatment is not clear, therefore, in a stimulating the process has a certain unpredictability, and may even cause side effects. 其次,刺激装置在长期植入后,由于手术的创伤以及植入材料的生物相容性问题往往会引起炎性反应,随着星形胶质细胞包囊的形成,电极界面的阻抗会明显增大,刺激效果显著减弱。 Secondly, after prolonged implantation the stimulation device, since the trauma of surgery and biocompatible implant materials problems tend to cause inflammatory reactions, with the formation of astrocytes encapsulated, the interface impedance of the electrode will increase significantly large, stimulating effect was significantly reduced. 此外,包囊也会影响电极周边的神经细胞存活,增大了电极和目标神经元的距离,进而严重影响深脑电刺激的治疗效果。 In addition, the cysts can also affect the survival of nerve cells surrounding the electrode, increasing the distance between the electrode and the target neurons, which would seriously affect the therapeutic effect of deep brain electrical stimulation. 另外,深脑电刺激较难实现对神经元的抑制。 Further, deep Brain Stimulation difficult to achieve inhibition of neurons.

发明内容 SUMMARY

[0005] 基于此,有必要提供一种监测和治疗效果较好且较为安全的帕金森氏病治疗装置。 [0005] Based on this, it is necessary to monitor and provide a more effective and safer treatment device for treating Parkinson's disease.

[0006] -种帕金森氏病治疗装置,包括电生理信号发生检测系统、给药系统、光刺激系统及中央处理系统,所述中央处理系统控制所述电生理信号发生检测系统、所述给药系统及所述光刺激系统; [0006] - Parkinson's disease treatment device types, including the electrophysiological signal generating detection systems, delivery systems, and optical stimulation system central processing system, said central processing system controls the electrical physiological signal detection system occurs, to the Chemical stimulation of the optical system and the system;

[0007] 其中,所述电生理信号发生检测系统包括用于检测目标区域的神经递质浓度和变化的神经递质传感器、用于记录神经组织细胞的局部场电位和神经电活动的记录电极和用于进行功能性电刺激对帕金森氏病患者进行治疗的刺激电极; [0007] wherein the electrical physiological signal generating detection system comprises a sensor for neurotransmitters and neurotransmitter concentration detecting a change in the target area, the local field potential electrode for recording nerve activity and recording of neural cells and functional electrical stimulation for Parkinson's disease treatment stimulation electrode;

[0008] 所述给药系统包括注射泵及微导管,所述中央处理系统控制所述注射泵通过微导管进行药物缓释; [0008] The drug delivery system comprises a syringe pump and the microcatheter, said central processing system controls the injection pump through a microcatheter Drug Delivery;

[0009] 所述光刺激系统包括波形发生器、光源及光纤,所述波形发生器控制所述光源发出的激光的频率,所述光源发出的激光传至所述光纤中用于对导入有光敏感基因的神经组织细胞进行光刺激治疗。 [0009] The optical system comprises a stimulus waveform generator, and an optical fiber light source, the waveform generator controls the frequency of the emitted laser light, laser light emitted from the light source is transmitted to the optical fiber for introducing light neural cells sensitive gene optical stimulation therapy.

[0010] 在其中一个实施例中,所述神经递质传感器为碳纤维微电极、钼微电极、钼铱微电极、铱微电极、碳纳米管微电极或导电聚合物微电极,所述神经递质传感器的直径为3〜 200微米。 [0010] In one embodiment, the neurotransmitter is a carbon fiber microelectrode sensors, micro molybdenum electrode, molybdenum microelectrodes iridium, iridium microelectrode, a conductive polymer or a carbon nanotube microelectrode microelectrode, said neurotransmitters diameter of the sensor mass 3 ~ 200 microns. toon] 在其中一个实施例中,所述神经递质传感器、所述记录电极及所述刺激电极形成电极阵列。 Toon] In one embodiment, the neurotransmitter sensor, the recording electrode and the stimulation electrode form an electrode array.

[0012] 在其中一个实施例中,所述神经递质传感器的数量、所述刺激电极的数量、所述记录电极的数量、所述微导管的数量及所述光纤的数量分别至少为1个。 [0012] In one embodiment, the number of the neurotransmitter sensor, the number of stimulation electrodes, the number of said recording electrodes, and the number of the microcatheter are the number of the optical fiber is at least one .

[0013] 在其中一个实施例中,所述电极阵列、所述微导管及所述光纤平行设置且结合在一起形成束状结构。 [0013] In one embodiment, the electrode array, the optical fiber and the microcatheter disposed in parallel and bonded together to form a bundle structure.

[0014] 在其中一个实施例中,所述给药系统通过微导管向神经组织细胞释放光感基因、 抗炎性因子、神经营养因子或血管生长因子。 [0014] In one embodiment, the light-sensitive gene delivery system to release neural cells through a microcatheter, anti-inflammatory factors, neurotrophic factors or angiogenic factors.

[0015] 在其中一个实施例中,所述光源发出的激光的波长为472nm或593nm。 [0015] In one embodiment, the wavelength of the laser light source is 472nm or 593nm.

[0016] 在其中一个实施例中,所述神经递质为多巴胺和谷氨酸中的至少一种。 [0016] In one embodiment, the neurotransmitter dopamine and at least one glutamic acid.

[0017] 上述帕金森氏病治疗装置工作时,首先中央处理系统控制电生理信号发生检测系统通过神经递质传感器检测神经递质的浓度和变化,同时通过记录电极检测神经组织细胞的电生理信号,从而可以更好的监测病症,中央处理系统根据反馈的信息控制波形信号发生器调节光源输出不同频率的激光,光源发出的激光传至光纤中用于对导入有光敏感基因的神经组织细胞进行光刺激治疗。 [0017] When the treatment device is operated, the central processing system first control signal generating electrophysiological Parkinson's disease detection system detects changes in the concentration of neurotransmitters and neurotransmitter by the above-described sensors, by the simultaneous recording electrophysiological signals detected by the electrodes of neural cells , which can better monitor the condition of the laser transmitted optical output light central processing system modulating different frequencies according to the feedback information control waveform signal generator of the laser, the light source for introducing light sensitive tissue of the gene nerves light stimulation therapy. 通过光刺激来兴奋或抑制神经元,达到调控神经回路的目的,从而达到治疗帕金森氏病的目的,而且激光只对导入了感光基因的神经组织细胞有作用,因此,该帕金森氏病治疗装置具有选择性和特异性。 Excitatory or inhibitory neurons to achieve the purpose of control of neural circuits, so as to achieve the purpose of treating Parkinson's disease, but only the laser effect on neural cells photosensitive introduced gene by stimulating light, therefore, the treatment of Parkinson's disease It means having a selectivity and specificity. 并且这种装置整合了刺激电极及给药系统,可以在治疗的过程中结合电刺激和药物缓释技术作为辅助手段提高治疗效果且更安全。 And such a stimulation electrode device integration and delivery systems may be combined with electrical stimulation and drug release during therapy technology as an adjunct to improve the therapeutic effect and more safety.

附图说明 BRIEF DESCRIPTION

[0018] 图1为一实施方式的帕金森氏病治疗装置的模块示意图; Schematic block device [0018] Figure 1 is one embodiment of the treatment of Parkinson's disease;

[0019] 图2为图1中电极阵列、微导管及光纤的结构示意图。 [0019] FIG. 2 is a schematic electrode array, the microcatheter and fiber structure 1 in FIG.

具体实施方式 Detailed ways

[0020] 下面结合附图对帕金森氏病治疗装置进行进一步说明。 BRIEF Parkinson's disease treatment device to be further described [0020] below in conjunction.

[0021] 如图1所示,一实施方式的帕金森氏病治疗装置100,用于对神经组织200进行检测和治疗,其包括中央处理系统110、电生理信号发生检测系统120、给药系统130及光刺激系统140。 [0021] As shown, a Parkinson's disease treatment apparatus 100 of the embodiment, the neural tissue 200 for detection and treatment, including a central processing system 110, electrophysiological signal generator 1120, delivery systems detection system 130 and 140 light stimulation system.

[0022] 中央处理系统110综合控制电生理信号发生检测系统120、给药系统130及光刺激系统140。 [0022] The central processing system 110 integrated control system electrophysiological signal detection occurs 120, 130 and a light delivery system stimulation system 140.

[0023] 在本实施方式中,电生理信号发生检测系统120包括用于检测目标区域的神经递质浓度和变化的神经递质传感器122、用于记录神经组织细胞的局部场电位和神经电活动的记录电极124和用于进行功能性电刺激对帕金森氏病患者进行治疗的刺激电极126。 [0023] In the present embodiment, the electrical physiological signal comprises detecting the occurrence of neurotransmitter concentration system 120 for detecting and variations nerve neurotransmitter target area sensor 122, and a local field potential recording electrical activity of nerve tissue nerve cells the stimulation electrodes 124 and recording electrodes for functional electrical stimulation to treat Parkinson's disease patients 126.

[0024] 神经递质传感器122检测神经组织200细胞中神经递质(如多巴胺或谷氨酸)的浓度和变化信息。 [0024] neurotransmitter concentration sensors 122 and 200 detect the cell change information in the nervous tissue of neurotransmitters (e.g., dopamine or glutamic acid) of. 记录电极124记录神经组织200细胞的电生理信号信息(包括局部场电位和神经电活动信号)。 124 recording electrodes recording physiological signals information 200 electrical nerve tissue cells (including the local field potential and nerve signal activity). 神经递质传感器122与记录电极124将检测得到生理信号反馈给中央处理系统110,中央处理系统110可以根据多种监测信息对神经组织200的病症判断更准确,能更好的监测病症,提高治疗的准确性。 Neurotransmitters recording electrode 124 and the sensor 122 will detect the physiological signal obtained is fed back to the central processing system 110, central processing system 110 according to a variety of monitoring information nerve tissue disorders 200 determines more accurate, better monitoring of the condition, the treatment to improve accuracy.

[0025] 中央处理系统110可以控制刺激电极126对帕金森氏病进行功能性电刺激治疗, 为帕金森氏病提供一种治疗手段。 [0025] The central processing system 110 may control the stimulation electrode 126 Parkinson's disease for functional electrical stimulation therapy, there is provided a method for the treatment of Parkinson's disease.

[0026] 在本实施方式中,神经递质传感器122、记录电极124及刺激电极126形成电极阵列。 [0026] In the present embodiment, the neurotransmitter sensor 122, the recording electrode 124 and the electrode 126 form an electrode array of stimulation. 神经递质传感器122、记录电极124及刺激电极126的数量分别为1个。 Neurotransmitters sensor 122, the recording electrode 124 and the number of stimulation electrodes 126 are respectively a.

[0027] 在其他实施方式中,神经递质传感器122的数量可以为多个,具体工作时,可以是多个神经递质传感器122监测同一种神经递质,也可以是多个神经递质传感器122对应监测不同种神经递质。 [0027] In other embodiments, the number of neurotransmitter sensor 122 may be a plurality, particularly when working may be a plurality of sensors 122 monitor the same neurotransmitter, a neurotransmitter, or may be a plurality of sensors neurotransmitter 122 correspond to monitor different neurotransmitters. 其中,神经递质传感器122可以为碳纤维微电极、钼微电极、钼铱微电极、铱微电极、碳纳米管微电极或导电聚合物微电极中的一种或多种,一般的神经递质传感器122的直径为3〜200 μ m。 Wherein neurotransmitter sensor 122 may be a carbon fiber microelectrode microelectrode molybdenum, iridium microelectrode molybdenum, iridium microelectrode or microelectrode conductive polymer carbon nanotube microelectrode in one or more, typically neurotransmitter diameter sensor 122 is 3~200 μ m. 根据不同的治疗要求,电极阵列还可以为神经递质传感器122,刺激电极126和记录电极124中的至少一种,而且神经递质传感器122、记录电极124 和刺激电极126的数量均可不相同,数量可以根据实际情况为一个或多个。 Depending on the therapeutic requirements, the electrode array sensor 122 may also be a neurotransmitter, at least one stimulating electrode 126 and the electrode 124 is recorded, and neurotransmitter sensor 122, the number of the recording electrode 124 and the electrode 126 can not stimulate the same, the number may be one or more of the actual situation.

[0028] 在本实施方式中,给药系统130包括注射泵132及微导管134。 [0028] In the present embodiment, the administration system 130 includes a syringe pump 132 and the microcatheter 134. 中央处理系统110 控制注射泵132通过微导管134对神经组织200进行药物缓释。 The central processing system 110 controls the syringe pump 132 Drug release neural tissue 200 through the microcatheter 134. 本实施方式的微导管134 的数量为1个。 Number microcatheter 134 of the present embodiment is a. 在其他的实施方式中,根据实际情况,微导管134的数量可以为多个,可以同时进行多种药物的缓释。 In other embodiments, the actual situation, the number of micro-catheter 134 may be a plurality and can be sustained release multiple drugs simultaneously.

[0029] 在本实施方式中,光刺激系统140包括波形信号发生器142、光源144及光纤146。 [0029] In the present embodiment, the light stimulation system 140 includes a waveform generator 142, a light source 144 and optical fiber 146. 波形发生器142控制光源144发出不同频率的激光。 The waveform generator 142 controls the light source 144 emit laser light of different frequencies. 光源144发出的激光传至光纤146中用于对导入有光敏感基因的神经组织200细胞进行光刺激治疗。 The light source 144 emits laser light 146 transmitted to the optical fiber 200 for introducing light sensitive nerve tissue cells a gene optical stimulation therapy. 光源发出的激光的波长为472nm或593nm。 Wavelength of the laser light source is 472nm or 593nm. 光纤的数量为1个。 Is a number of optical fibers. 在其他实施方式中,光纤146的数量可以为多个,多个光纤146可以同时对神经组织200的多个部位实行光刺激治疗。 In other embodiments, the number of fibers 146 may be a plurality, the plurality of optical fibers 146 can be implemented simultaneously treatment of a plurality of stimulation of nerve tissue site 200.

[0030] 在本实施方式中,给药系统130有两方面的作用,一方面是:在光刺激治疗前,首先通过给药系统130向神经组织200细胞释放光感基因并转入到与相关回路的神经元内并表达,然后通过光刺激引起目标神经元的兴奋或抑制。 [0030] In the present embodiment, the delivery system 130 has two roles, one is: before light stimulation treatment, 200 is first released into the cells by administration of nervous tissue system 130 and transferred to the light-sensitive genes associated with and the expression of neuronal circuits, and causing the target neurons excited by light stimulation or inhibition. 导入的光敏感基因对蓝色(波长=472nm)和黄色(波长=593nm)激光特别敏感。 Introduced gene is particularly sensitive to light-sensitive blue (wavelength = 472nm) and yellow (wavelength = 593nm) laser. 光源144发出蓝色或黄色激光通过光纤146传至神经组织200细胞中进行照射,蓝光刺激表达有兴奋型通道蛋白基因的神经元,将兴奋该类神经元,其中,兴奋型通道蛋白基因为ChR2(Channelrhodopsin-2);而用黄光刺激表达有抑制型通道蛋白基因的神经元,将抑制该类神经元,其中,抑制型通道蛋白基因为NpHR(Helorhodopsin)。 The light source 144 emits blue or yellow laser light transmitted through the optical fiber 146 cells of neural tissue 200 is irradiated with a blue light stimulation of excitatory neurons expressing channel protein gene, the class excitatory neurons, wherein excitatory channel protein gene ChR2 (channelrhodopsin-2); and a yellow light stimulates the expression of inhibitory neurons have channel protein gene, will inhibit this class of neurons, wherein the inhibitory gene is the channel NpHR (Helorhodopsin). 通过兴奋或抑制就能调控神经回路,从而达到治疗帕金森氏病的目的。 By excitatory or inhibitory neural circuits can be regulated, so as to achieve the purpose of treatment of Parkinson's disease. 由于蓝色或黄色激光只对导入了光敏感基因的细胞起作用,因此该装置具有选择性和特异性,并且能有效兴奋或抑制神经元。 Since the laser only blue or yellow, so that the device has a selective and specific functions of the light-sensitive cells into which a gene, and can be effectively neuronal excitatory or inhibitory.

[0031] 另一方面,在治疗过程中,由于手术的创伤以及植入材料的生物相容性问题往往会引起炎性反应,导致星形胶质细胞包囊的形成和周围神经元的死亡。 [0031] On the other hand, in the course of treatment, and the problem of biocompatibility due to trauma surgical implant materials tend to cause inflammation, leading to death of astrocytes encapsulated and peripheral neurons. 这样,就会严重影响电刺激治疗和光刺激治疗的效果。 In this way, it will seriously affect the electrical stimulation therapy and light stimulation therapy. 当炎性反应产生时,中央处理系统110根据反馈得到的信息,控制给药系统130进行抗炎性因子的释放以缓解炎性。 When the inflammatory response, the central processing system 110 according to the feedback information obtained, the control system 130 for releasing the administration of anti-inflammatory factor to alleviate inflammation. 另外,在治疗过程中,中央处理系统110也可以根据反馈得到的信息,控制给药系统130进行神经营养因子的释放以促进神经的生长和活性,或者进行血管生长因子的释放以增强神经组织200细胞区域的微循环,促进神经组织200的修复。 Further, during treatment, the central processing system 110 may be obtained according to the feedback control system 130 for releasing the administration of neurotrophic factors to promote growth and activity of nerves, or by the release of angiogenic growth factors to enhance neural tissue 200 microcirculation cell area, promote nerve tissue repair 200.

[0032] 如图2所示,在本实施方式中,电极阵列、微导管134及光纤146平行设置,并且通过固定装置300固定结合在一起形成束状结构。 [0032] As shown in FIG. 2, in the present embodiment, the electrode array, the optical fiber 146 and the microcatheter 134 are arranged in parallel, and bonded together to form a bundle structure is fixed by fixing means 300.

[0033] 上述帕金森氏病治疗装置工作时,首先,中央处理系统110控制电生理信号发生检测系统120通过神经递质传感器122检测神经递质的浓度和变化,同时通过记录电极124 检测神经组织200细胞的电生理信号,更好的监测病症,然后,中央处理系统110根据反馈的信息控制波形信号发生器142调节光源144输出不同频率的激光,光源144发出的激光传至光纤146中用于对导入有光敏感基因的神经组织200细胞进行光刺激治疗。 [0033] The device operates Parkinson's disease treatment, first of all, the control 110 electrophysiological signal central processing system 120 and by changing the concentration of neurotransmitters detecting sensor 122 detecting the occurrence of neurotransmitter systems, while the detection electrode 124 by recording neural tissue electrophysiological signal 200 cells, better monitoring condition, then the central processing system 110 142 144 adjusts the laser light source of the laser output different frequencies, emitted by light source 144 according to the feedback control information transmitted waveform signal generator 146 for the optical fiber 200 cells are introduced into the light sensitive genes optical nerve tissue stimulation therapy. 通过光刺激来兴奋或抑制神经元,达到调控神经回路的目的,从而达到治疗帕金森氏病的目的,而且激光只对导入了感光基因的神经组织细胞有作用,因此,该帕金森氏病治疗装置具有选择性和特异性。 Excitatory or inhibitory neurons to achieve the purpose of control of neural circuits, so as to achieve the purpose of treating Parkinson's disease, but only the laser effect on neural cells photosensitive introduced gene by stimulating light, therefore, the treatment of Parkinson's disease It means having a selectivity and specificity. 并且这种装置整合了刺激电极126及给药系统130,可以在治疗的过程中结合电刺激和药物缓释技术作为辅助手段提高治疗效果且更安全。 And this integration means 126 and the stimulation electrode delivery system 130 can be used as an adjunct to enhance the therapeutic effect combined with electrical stimulation and drug release during therapy techniques safer.

[0034] 以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。 [0034] The above embodiments are only expressed several embodiments of the present invention, and detailed description thereof is more specific, but can not therefore be understood as limiting the scope of the present invention. 应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。 It should be noted that those of ordinary skill in the art, without departing from the spirit of the present invention, can make various changes and modifications, which fall within the protection scope of the present invention. 因此,本发明专利的保护范围应以所附权利要求为准。 Therefore, the protection scope of the present invention should be subject to the appended claims.

Claims (8)

1. 一种帕金森氏病治疗装置,其特征在于,包括电生理信号发生检测系统、给药系统、 光刺激系统及中央处理系统,所述中央处理系统控制所述电生理信号发生检测系统、所述给药系统及所述光刺激系统; 其中,所述电生理信号发生检测系统包括用于检测目标区域的神经递质浓度和变化的神经递质传感器、用于记录神经组织细胞的局部场电位和神经电活动的记录电极和用于进行功能性电刺激对帕金森氏病患者进行治疗的刺激电极; 所述给药系统包括注射泵及微导管,所述中央处理系统控制所述注射泵通过微导管进行药物缓释; 所述光刺激系统包括波形发生器、光源及光纤,所述波形发生器控制所述光源发出的激光的频率,所述光源发出的激光传至所述光纤中用于对导入有光敏感基因的神经组织细胞进行光刺激治疗。 An Parkinson's disease treatment apparatus, characterized by comprising detecting electrophysiological signal generating systems, delivery systems, and optical stimulation system central processing system, said central processing system controls the electrophysiological signal generating detection system, the drug delivery system and the stimulation optical system; wherein the electrical physiological signal detection system comprises a neurotransmitter concentration and the change target region for detecting neurotransmitters sensor is used to record local field neural cells recording electrode potentials and nerve activity and functional electrical stimulation for Parkinson's disease treatment stimulation electrodes; said drug delivery system comprises a syringe pump and the microcatheter, said central processing system controls the injection pump drug release through a microcatheter; system comprising the optical stimulus waveform generator, and an optical fiber light source, the waveform generator controls the frequency of laser light emitted by the light source, the laser light emitted is transmitted by the optical fiber light stimulation therapy to the tissue cells to a gene introduced into the light-sensitive nerve.
2. 根据权利要求1所述的帕金森氏病治疗装置,其特征在于,所述神经递质传感器为碳纤维微电极、钼微电极、钼铱微电极、铱微电极、碳纳米管微电极或导电聚合物微电极,所述神经递质传感器的直径为3~200微米。 The Parkinson's disease treatment device according to claim 1, wherein the neurotransmitter is a carbon fiber microelectrode sensors, micro molybdenum electrode, molybdenum microelectrodes iridium, iridium microelectrode or a carbon nanotube microelectrode conductive polymers microelectrodes, the diameter of the neurotransmitter sensor 3 to 200 micrometers.
3. 根据权利要求1或2所述的帕金森氏病治疗装置,其特征在于,所述神经递质传感器、所述记录电极及所述刺激电极形成电极阵列。 The Parkinson's disease treatment apparatus of claim 1 or claim 2, wherein the neurotransmitter sensor, the recording electrode and the stimulation electrode form an electrode array.
4. 如权利要求3所述的帕金森氏病治疗装置,其特征在于,所述神经递质传感器的数量、所述刺激电极的数量、所述记录电极的数量、所述微导管的数量及所述光纤的数量分别至少为1个。 4. The Parkinson's disease treatment device according to claim 3, wherein the number of the neurotransmitter sensor, the number of stimulation electrodes, the number of said recording electrodes, and the number of the microcatheter the number of optical fibers is at least 1, respectively.
5. 根据权利要求3所述的帕金森氏病治疗装置,其特征在于,所述电极阵列、所述微导管及所述光纤平行设置且结合在一起形成束状结构。 The Parkinson's disease treatment device according to claim 3, wherein said electrode array, said optical fiber and said microcatheter disposed in parallel and bonded together to form a bundle structure.
6. 根据权利要求1所述的帕金森氏病治疗装置,其特征在于,所述给药系统通过微导管向神经组织细胞释放光感基因、抗炎性因子、神经营养因子或血管生长因子。 6. Parkinson's disease treatment device according to claim 1, wherein said light-sensitive gene delivery system to release neural cells through a microcatheter, anti-inflammatory factors, neurotrophic factors or angiogenic factors.
7. 根据权利要求1所述的帕金森氏病治疗装置,其特征在于,所述光源发出的激光的波长为472nm或593nm。 7. Parkinson's disease treatment device according to claim 1, wherein the wavelength of the laser light source is 472nm or 593nm.
8. 根据权利要求1所述的帕金森氏病治疗装置,其特征在于,所述神经递质为多巴胺和谷氨酸中的至少一种。 8. The Parkinson's disease treatment device according to claim 1, wherein said at least one neurotransmitter dopamine and glutamic acid.
CN 201210275424 2012-08-03 2012-08-03 Parkinson's disease treatment device CN102793973B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210275424 CN102793973B (en) 2012-08-03 2012-08-03 Parkinson's disease treatment device

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210275424 CN102793973B (en) 2012-08-03 2012-08-03 Parkinson's disease treatment device

Publications (2)

Publication Number Publication Date
CN102793973A CN102793973A (en) 2012-11-28
CN102793973B true CN102793973B (en) 2014-10-29

Family

ID=47193436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210275424 CN102793973B (en) 2012-08-03 2012-08-03 Parkinson's disease treatment device

Country Status (1)

Country Link
CN (1) CN102793973B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103071246B (en) * 2013-02-19 2015-09-09 重庆大学 Prosthetic devices near-infrared light to stimulate nerves
CN105233413B (en) * 2015-08-21 2018-04-10 魏诗荣 Based on the diagnosis and treatment of tumors of the minimally invasive interventional catheter apparatus
FR3045391A1 (en) * 2015-12-17 2017-06-23 Commissariat Energie Atomique An implantable device for optical stimulation of the brain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440256A (en) 2000-05-08 2003-09-03 布雷恩斯盖特有限公司 Method and apparatus for stimulating sphenopalatine ganglion to modify properties of BBB and cerebral blood flow
CN101262904A (en) 2005-09-15 2008-09-10 皇家飞利浦电子股份有限公司 Apparatus and method for electrostimulation/sensing in vivo
EP2474339A1 (en) 2006-12-15 2012-07-11 Nasophlex B.V. Resuscitation device for resuscitation by stimulating an auricle of a human ear

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10318071A1 (en) * 2003-04-17 2004-11-25 Forschungszentrum Jülich GmbH Device for desynchronization of neuronal brain activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440256A (en) 2000-05-08 2003-09-03 布雷恩斯盖特有限公司 Method and apparatus for stimulating sphenopalatine ganglion to modify properties of BBB and cerebral blood flow
CN101262904A (en) 2005-09-15 2008-09-10 皇家飞利浦电子股份有限公司 Apparatus and method for electrostimulation/sensing in vivo
EP2474339A1 (en) 2006-12-15 2012-07-11 Nasophlex B.V. Resuscitation device for resuscitation by stimulating an auricle of a human ear

Also Published As

Publication number Publication date
CN102793973A (en) 2012-11-28

Similar Documents

Publication Publication Date Title
EP1359977B1 (en) Photodynamic stimulation device
US8591419B2 (en) Methods and devices for modulating cellular activity using ultrasound
US8498708B2 (en) Integrated system and method for treating disease using cognitive-training and brain stimulation and computerized magnetic photo-electric stimulator (CMPES)
ES2608498T3 (en) Systems, methods and compositions for optical stimulation of target cells
Goosens et al. NMDA receptors are essential for the acquisition, but not expression, of conditional fear and associative spike firing in the lateral amygdala
US8936630B2 (en) Optical stimulation therapy
Fu et al. A cortical circuit for gain control by behavioral state
Fuller et al. Reassessment of the structural basis of the ascending arousal system
Sotres-Bayon et al. Emotional perseveration: an update on prefrontal-amygdala interactions in fear extinction
Weinberger et al. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease
JP4311904B2 (en) Stimulation method and apparatus of the pterygopalatine ganglion in order to improve the properties of the blood-brain barrier and cerebral blood flow
Yamamoto et al. Successful execution of working memory linked to synchronized high-frequency gamma oscillations
Bikson et al. Effects of uniform extracellular DC electric fields on excitability in rat hippocampal slices in vitro
US20120253261A1 (en) Systems and methods for optogenetic modulation of cells within a patient
AU2011343763B2 (en) Devices, systems and methods for the treatment of medical disorders
Schiller et al. Cellular mechanisms underlying antiepileptic effects of low-and high-frequency electrical stimulation in acute epilepsy in neocortical brain slices in vitro
US20140058189A1 (en) Systems and methods using brain stimulation for treating disorders
Boraud et al. High frequency stimulation of the internal Globus Pallidus (GPi) simultaneously improves parkinsonian symptoms and reduces the firing frequency of GPi neurons in the MPTP-treated monkey
US20070100398A1 (en) Neural stimulation system and optical monitoring systems and methods
Nichols et al. Vagus nerve stimulation modulates cortical synchrony and excitability through the activation of muscarinic receptors
US9101759B2 (en) Materials and approaches for optical stimulation of the peripheral nervous system
Gradinaru et al. Optical deconstruction of parkinsonian neural circuitry
Witter et al. Strength and timing of motor responses mediated by rebound firing in the cerebellar nuclei after Purkinje cell activation
Freeman et al. Selective activation of neuronal targets with sinusoidal electric stimulation
US9162052B2 (en) Treatment of language, behavior and social disorders

Legal Events

Date Code Title Description
C06 Publication
C10 Request of examination as to substance
C14 Granted